
Panelists challenge the belief that testosterone fuels prostate cancer, explain PSA on therapy and TRAVERSE BPH data, and weigh Schedule III status.
Men with overactive bladder and lower urinary tract symptoms who receive combination therapy are more likely to report improvement in symptoms than those who receive only one medication, according to results of a study recently reported in JAMA (2006; 296:2319-28).





